Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000600621 | Liver | HCC | glucose metabolic process | 128/7958 | 196/18723 | 8.60e-11 | 3.06e-09 | 128 |
GO:005134822 | Liver | HCC | negative regulation of transferase activity | 166/7958 | 268/18723 | 8.97e-11 | 3.18e-09 | 166 |
GO:190018012 | Liver | HCC | regulation of protein localization to nucleus | 95/7958 | 136/18723 | 9.26e-11 | 3.26e-09 | 95 |
GO:00463952 | Liver | HCC | carboxylic acid catabolic process | 149/7958 | 236/18723 | 1.11e-10 | 3.87e-09 | 149 |
GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
GO:007149622 | Liver | HCC | cellular response to external stimulus | 191/7958 | 320/18723 | 3.40e-10 | 1.13e-08 | 191 |
GO:200124212 | Liver | HCC | regulation of intrinsic apoptotic signaling pathway | 109/7958 | 164/18723 | 4.52e-10 | 1.45e-08 | 109 |
GO:001624111 | Liver | HCC | regulation of macroautophagy | 96/7958 | 141/18723 | 6.82e-10 | 2.14e-08 | 96 |
GO:007233122 | Liver | HCC | signal transduction by p53 class mediator | 108/7958 | 163/18723 | 7.14e-10 | 2.23e-08 | 108 |
GO:001063912 | Liver | HCC | negative regulation of organelle organization | 204/7958 | 348/18723 | 7.67e-10 | 2.37e-08 | 204 |
GO:004346722 | Liver | HCC | regulation of generation of precursor metabolites and energy | 89/7958 | 130/18723 | 1.84e-09 | 5.35e-08 | 89 |
GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
GO:200006022 | Liver | HCC | positive regulation of ubiquitin-dependent protein catabolic process | 76/7958 | 107/18723 | 2.06e-09 | 5.79e-08 | 76 |
GO:004424222 | Liver | HCC | cellular lipid catabolic process | 134/7958 | 214/18723 | 2.07e-09 | 5.79e-08 | 134 |
GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
GO:003243612 | Liver | HCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/7958 | 90/18723 | 2.79e-09 | 7.55e-08 | 66 |
GO:190547511 | Liver | HCC | regulation of protein localization to membrane | 113/7958 | 175/18723 | 2.90e-09 | 7.78e-08 | 113 |
GO:003461412 | Liver | HCC | cellular response to reactive oxygen species | 102/7958 | 155/18723 | 3.70e-09 | 9.89e-08 | 102 |
GO:001082112 | Liver | HCC | regulation of mitochondrion organization | 96/7958 | 144/18723 | 3.82e-09 | 1.02e-07 | 96 |
GO:000734611 | Liver | HCC | regulation of mitotic cell cycle | 255/7958 | 457/18723 | 4.96e-09 | 1.30e-07 | 255 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05213 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa04213 | Colorectum | AD | Longevity regulating pathway - multiple species | 27/2092 | 62/8465 | 8.72e-04 | 5.96e-03 | 3.80e-03 | 27 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKT1 | SNV | Missense_Mutation | novel | c.618N>T | p.Arg206Ser | p.R206S | P31749 | protein_coding | tolerated(0.32) | benign(0.023) | TCGA-A7-A13G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | | c.155N>G | p.Leu52Arg | p.L52R | P31749 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49G>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49N>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49N>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
AKT1 | SNV | Missense_Mutation | rs121434592 | c.49N>A | p.Glu17Lys | p.E17K | P31749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | 178101884 | GSK-690693 | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | AZD4547 | | 26351323 |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | PTX-200 | | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | CHEMBL3137336 | UPROSERTIB | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | 249565578 | IPATASERTIB | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | Ipatasertib | IPATASERTIB | 27872130 |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | GAMBOGIC AMIDE | GAMBOGIC AMIDE | 17911251 |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | GDC-0068 | IPATASERTIB | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | SOTRASTAURIN | SOTRASTAURIN | |
207 | AKT1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSPORTER, TRANSCRIPTION FACTOR, DRUG RESISTANCE | inhibitor | MK-2206 | MK-2206 | |